Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
|Articles|September 2, 2020
- Pharmaceutical Technology-09-02-2020
- Volume 44
- Issue 9
Oral Solid Dosage Equipment
Author(s)Pharmaceutical Technology Editors
GEA has expanded, integrated, and consolidated its ConsiGma continuous oral solid dosage equipment, allowing fully configurable systems that can be connected to new or existing facilities, including third-party equipment.
GEA has expanded, integrated, and consolidated its ConsiGma continuous oral solid dosage equipment, allowing fully configurable systems that can be connected to new or existing facilities, including third-party equipment.
The newly defined ConsiGma 4.0 modules can be used to transform an individual unit operation (e.g., granulation) from batch to a stand-alone, continuous operation. The system uses advanced process control software and the company’s newly developed Conductor 4.0 control system, which is compatible with supervisory control and data acquisition systems and connects to the Industrial Internet of Things.
Although the system is configurable, standard, core elements are available “off-the-shelf.” Standardization or mass customization makes continuous manufacturing equipment more affordable for a wider range of users and expedites delivery.
Articles in this issue
about 5 years ago
Moving Forward in Serializationabout 6 years ago
Preparing Pandemic Vaccine Capacityabout 6 years ago
Tracking API Quality During a Pandemicabout 6 years ago
Capsule Innovations: Speeding Up Drug Developmentabout 6 years ago
Manufacturing Drug–Device Combination Productsabout 6 years ago
Advancing Understanding of a Traditional Techniqueabout 6 years ago
Pharmacovigilance Under Scrutiny: Why Companies are Falling Shortabout 6 years ago
Pharmacopoeia Compliance: A Practical Guideabout 6 years ago
Streamlining Method Transfer Across Global SitesRelated to this article
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
Trending on Pharmaceutical Technology
1
Risk-Based Life Cycle Management of Master Production and Control Records to Strengthen Data Integrity and GMP Inspection Readiness Part 2: Practical Considerations for CGMP Documentation Systems
2
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
3
PharmTech’s Weekly Roundup—September 25, 2026
4
CPHI Milan: USP Benchmarks Reshape Procurement Incentives
5